Toledo Community Oncology Program Logo

Member Login Phone: 419-843-6147
Email: info@tcop.info

Trial Search

TCOP conducts a variety of clinical trials every year. In fact, there are over 100 trials running at any given time, each specifically focusing on a particular type of cancer research. To find out if there are current trials running, addressing a specific form of cancer, click on a cancer type in the list below.


  • Allocation List
    • Acuity Score
      • RU021212l
        • Randomized Phase II Double Blind Study of Adjuvant Regorafenib vs Placebo in Patients with Node Positive Esophageal Cancer that Completed Pre-operative Therapy
  • Assessment Study
    • Unspecified
      • RU221501I
        • Phase III Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects with Cancer related Venous Thromboembolism
  • Bladder
    • Bladder
      • S1314 (CIRB)
        • Testing the Use of the Co-Expression Extrapolation Program to Predict Response to Usual Chemotherapy in Patients with Localized, Muscle Invasive Bladder Cancer
  • Brain
    • Glioblastoma
      • A221101
        • A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiform
      • A071102 (CIRB)
        • Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
  • Breast
    • Breast
      • SCUSF 1102
        • A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients
      • EA1131 (CIRB) - (Suspended)
        • Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
      • NRG-BR003 (CIRB)
        • A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
    • Cancer Control
      • E2112 (CIRB)
        • A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
    • Early Stage
      • N083E - (Suspended)
        • Phase II Safety Study of Docetaxel and Carboplatin in Combination with Trastuzumab and Lapatinib in Early Breast Cancer .......................study closed to accrual on 1/14/15 but sites must continue IRB approvals so I have marked the database as suspended
    • HER2 Negative
      • NSABP B-55 (CIRB)
        • Randomized Double Blind Parallel Group, Placebo-Controlled, Multi-center Phase III Study to Assess the Efficacy and Safety of Olaparib Vs. Placebo as Adjuvant Treatment in Patients with Germline BRCA 1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer who Have Completed Definitive Local Treatment and Neoadjuvant and Adjuvant Chemotherapy
    • HER2+
      • RU011301I
        • Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients with Human Epidermal Growth Factor Receptor 2 HER2+ Breast Cancer
  • Cancer Control
    • Cancer Control
      • E1Z11
        • A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
  • Gastrointestinal
    • Colorectal
      • S1406 (CIRB) - (Suspended)
        • Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
      • OSU 2012C0123
        • Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome
      • RU021407I
        • Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients with Refractory Metastatic Colorectal Cancer
    • Pancreas
      • RTOG-0848 (CIRB)
        • Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancrease Adenocarcinoma
      • S1505 (CIRB)
        • Randomized Phase II Study of Perioperative mFolfirinox vs. Gemcitabine/NAB-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
  • Genitourinary
    • Prostate
      • RTOG-0815 (CIRB)
        • A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate Risk Prostate Cancer----QOL Closed 4/11/2912
      • RTOG-0924 (CIRB)
        • Androgen Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial
      • S1216 (CIRB)
        • Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
      • A031201 (CIRB)
        • Phase III Trial of Enzalutamide vs. Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
    • Renal Cell
      • S0931 (CIRB)
        • Phase III Study: Everolimus for Renal Cancer Ensuing Surgical Therapy
  • Head and Neck
    • Head/Neck
      • RTOG-0920 (CIRB)
        • A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer
  • Hematology
    • B-Cell Lymphoma
      • E1412
        • Randomized Phase II Study of Lenalidomide R-CHOP (R2CHOP) vs R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma
    • Chronic Lymphocytic Leukemia
      • E1912 (CIRB)
        • A Randomized Phase III Study of PCI-32765-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
    • Follicular Lymphoma
      • CALGB-50904
        • Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib and Bendamustine in Patients with Untreated Follicular Lympoma
      • B3281006
        • Phase 3, Randomized, Double-Blind Study, of PF-05280586 vs. Rituximab for the 1st Line Treatment of Patients with CD20-Positive, Low Tumor Burden, Follicular Lymphoma
    • Hodgkins
      • CALGB-50801
        • A Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
    • Multiple Myeloma
      • S1211
        • A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
      • OSU 10155
        • Surveillance, Contact, and Research for MGUS, Myeloma, and Amyloidosis-----------------TCOP opened 1/9/14
      • S1304 - (Suspended)
        • A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease.
  • Lung
    • Lung
      • A151216 (CIRB)
        • Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
      • E4512 (CIRB)
        • Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer - Crizotinib vs. Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase Fusion Protein
    • Non-Small Cell
      • ABI-007-NSCL-003
        • Randomized, Phase 3, Open-Label, Multicenter, Safety and Efficacy Study to Evaluate nab-paclitaxel as Maintenance Treatment after Induction with Nab-Paclitaxel plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer
      • A081105 (CIRB)
        • Randomized Doub le Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resectedc Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer
      • BPI-2358-103
        • Randomized, Phase 3 Assessment of Second Line Chemotherapy with Docetaxel and Plinabulin Compared to Docetaxel Alone in Patients with Advanced Non-Small Cell Lung Cancer with at Least 1 large Lung Lesion
  • Melanoma
    • Melanoma
      • EA6134 (CIRB)
        • Randomized Phase III Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab and Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma (approval to open at TCI received 8/3/15)
      • EA6141 (CIRB)
        • Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim vs. Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
  • Oral Cavity/Oropharynx
    • Oropharynx
      • GT-201 Galera
        • Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of Intravenous GC4419 on the Incidence and Duration of Severe Oral Mucositis in Patients Receiving Post-Operative or Definitive Therapy with Single-Agent, Cisplatin plus IMRT for Locally Advanced, Non-Metastatic Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
  • Pharmaceutical - Limited Sites.
    • Lung
      • MO22097 ( PrE0502 ) - (Suspended)
        • Open-Label, Randomized, Phase IIIB Trial Evaluating the Efficacy and Safety of Standard of Care +/- continuous Bevacizumab Treatment Beyond Progression of Disease in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer After First-Line Treatment with Bevacizumab Plus a Platinum Doublet-containing Chemotherapy---------TCOP opened study 10/12/2011 Study was closed to enrollment 3/11/15, but sponsor requires us to keep study opened and IRB approved until data completion. For this reason I have marked study suspended, and IRB review will continue until notifed by sponsor. Expected date of data completion is June, 2016
    • Metastatic Breast
      • ABI-007-MBC-001 - (Suspended)
        • A Phase 2/3, Multi-Center, Open-Label, Randomized Study Of Weekly Nab®-Paclitaxel In Combination With Gemcitabine Or Carboplatin, Compared To Gemcitabine/Carboplatin, As First Line Treatment In Subjects With Er, Pgr, And Her2 Negative (Triple Negative) Metastatic Breast Cancer -------------------TCOP opened 5/14/14
    • Metastatic Colorectal
      • OBS13597-OZONE
        • Prospective International Observational Cohort Non-Comparative Study Describing The Safety And Effectiveness Of ZALTRAP® administered In Combination With FOLFIRI For The Treatment Of Patients With Metastatic Colorectal Cancer In Current----------------TCOP opened 3/12/14 Clinical Practice: A Post-Authorization Safety Study (PASS)
    • Non-Hodgkins Lymphoma
      • PIX306
        • Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine and Rituximab in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma who have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant----------------------TCOP opened 4/13/11
      • PrE0401
        • Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients with Previously Untreated Low Tumor Burden Indolent Non-Hodgkin’s Lymphoma--------------TCOP opened 10/29/13
  • Skin
    • Skin Cancer
      • S1320 (CIRB)
        • Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which has Spread
  • Unspecified
    • Carcinoid Tumor
      • A021202 - (Suspended)
        • Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors
    • Patient Satisaction Survey
      • N0392
        • Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials (1 page information consent approved IRB 11/14/07)